Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Individual and Sexual Network Predictors of HIV Incidence Among Men Who Have Sex With Men in Nigeria.

Nowak RG, Mitchell A, Crowell TA, Liu H, Ketende S, Ramadhani HO, Ndembi N, Adebajo S, Ake J, Michael NL, Blattner WA, Baral SD, Charurat ME.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):444-453. doi: 10.1097/QAI.0000000000001934.

2.

Brief Report: Body Mass Index and Cognitive Function Among HIV-1-Infected Individuals in China, India, and Nigeria.

Jumare J, El-Kamary SS, Magder L, Hungerford L, Umlauf A, Franklin D, Ghate M, Abimiku A, Charurat M, Letendre S, Ellis RJ, Mehendale S, Blattner WA, Royal W 3rd, Marcotte TD, Heaton RK, Grant I, McCutchan JA.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):e30-e35. doi: 10.1097/QAI.0000000000001906.

PMID:
30422905
3.

Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV.

Nowak RG, Bentzen SM, Ravel J, Crowell TA, Dauda W, Ma B, Liu H, Blattner WA, Baral SD, Charurat ME; TRUST/RV368 Study Group.

AIDS Res Hum Retroviruses. 2019 Mar;35(3):267-275. doi: 10.1089/AID.2018.0158. Epub 2018 Oct 17.

PMID:
30215262
4.

Plasma HIV RNA level is associated with neurocognitive function among HIV-1-infected patients in Nigeria.

Jumare J, El-Kamary SS, Magder L, Hungerford L, Ndembi N, Aliyu A, Dakum P, Umlauf A, Cherner M, Abimiku A, Charurat M, Blattner WA, Royal W 3rd.

J Neurovirol. 2018 Dec;24(6):712-719. doi: 10.1007/s13365-018-0667-8. Epub 2018 Aug 30.

5.

Cognitive Function Among Antiretroviral Treatment-Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria.

Jumare J, Ndembi N, El-Kamary SS, Magder L, Hungerford L, Burdo T, Eyzaguirre LM, Dakum P, Umlauf A, Cherner M, Abimiku A, Charurat M, Blattner WA, Royal W 3rd.

Clin Infect Dis. 2018 Apr 17;66(9):1448-1453. doi: 10.1093/cid/cix1019.

6.

Phylodynamic analysis to inform prevention efforts in mixed HIV epidemics.

Volz EM, Ndembi N, Nowak R, Kijak GH, Idoko J, Dakum P, Royal W, Baral S, Dybul M, Blattner WA, Charurat M.

Virus Evol. 2017 Jul 28;3(2):vex014. doi: 10.1093/ve/vex014. eCollection 2017 Jul.

7.

Stigma, access to healthcare, and HIV risks among men who sell sex to men in Nigeria.

Crowell TA, Keshinro B, Baral SD, Schwartz SR, Stahlman S, Nowak RG, Adebajo S, Blattner WA, Charurat ME, Ake JA.

J Int AIDS Soc. 2017 Apr 20;20(1):21489. doi: 10.7448/IAS.20.01.21489.

8.

Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria.

Jumare J, Sunshine S, Ahmed H, El-Kamary SS, Magder L, Hungerford L, Burdo T, Eyzaguirre LM, Umlauf A, Cherner M, Abimiku A, Charurat M, Li JZ, Blattner WA, Royal W 3rd.

J Neurovirol. 2017 Jun;23(3):474-482. doi: 10.1007/s13365-017-0520-5. Epub 2017 Feb 27.

9.

Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria.

Nowak RG, Bentzen SM, Ravel J, Crowell TA, Dauda W, Ma B, Liu H, Blattner WA, Baral SD, Charurat ME; TRUSTRV368 Study Group.

AIDS. 2017 Mar 27;31(6):857-862. doi: 10.1097/QAD.0000000000001409.

10.

High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria.

Keshinro B, Crowell TA, Nowak RG, Adebajo S, Peel S, Gaydos CA, Rodriguez-Hart C, Baral SD, Walsh MJ, Njoku OS, Odeyemi S, Ngo-Ndomb T, Blattner WA, Robb ML, Charurat ME, Ake J; TRUST/RV368 Study Group.

J Int AIDS Soc. 2016 Dec 7;19(1):21270. doi: 10.7448/IAS.19.1.21270. eCollection 2016.

11.

JAIDS: Transitions, Evolution, and Impact.

Volberding P, Blattner WA.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):1-2. No abstract available.

12.

Online Sex-Seeking Among Men who have Sex with Men in Nigeria: Implications for Online Intervention.

Stahlman S, Nowak RG, Liu H, Crowell TA, Ketende S, Blattner WA, Charurat ME, Baral SD; TRUST/RV368 Study Group.

AIDS Behav. 2017 Nov;21(11):3068-3077. doi: 10.1007/s10461-016-1437-3.

13.

Prevalence of Anal High-Risk Human Papillomavirus Infections Among HIV-Positive and HIV-Negative Men Who Have Sex With Men in Nigeria.

Nowak RG, Gravitt PE, He X, Ketende S, Dauda W, Omuh H, Blattner WA, Charurat ME; TRUST Study Group.

Sex Transm Dis. 2016 Apr;43(4):243-8. doi: 10.1097/OLQ.0000000000000431.

14.

Associations between Cognition, Gender and Monocyte Activation among HIV Infected Individuals in Nigeria.

Royal W 3rd, Cherner M, Burdo TH, Umlauf A, Letendre SL, Jumare J, Abimiku A, Alabi P, Alkali N, Bwala S, Okwuasaba K, Eyzaguirre LM, Akolo C, Guo M, Williams KC, Blattner WA.

PLoS One. 2016 Feb 1;11(2):e0147182. doi: 10.1371/journal.pone.0147182. eCollection 2016.

15.

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.

Dolcetti R, Giagulli C, He W, Selleri M, Caccuri F, Eyzaguirre LM, Mazzuca P, Corbellini S, Campilongo F, Marsico S, Giombini E, Muraro E, Rozera G, De Paoli P, Carbone A, Capobianchi MR, Ippolito G, Fiorentini S, Blattner WA, Lu W, Gallo RC, Caruso A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14331-6. doi: 10.1073/pnas.1514748112. Epub 2015 Nov 2. Erratum in: Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E7033.

16.

The immediate eff ect of the Same-Sex Marriage Prohibition Act on stigma, discrimination, and engagement on HIV prevention and treatment services in men who have sex with men in Nigeria: analysis of prospective data from the TRUST cohort.

Schwartz SR, Nowak RG, Orazulike I, Keshinro B, Ake J, Kennedy S, Njoku O, Blattner WA, Charurat ME, Baral SD; TRUST Study Group.

Lancet HIV. 2015 Jul;2(7):e299-306.

17.

Analysis of reverse transcriptase and protease genes of HIV for antiretroviral drug resistance in treatment-exposed Jamaican pediatrics.

Ramkissoon AP, Amarakoon II, Hamilton CL, Pierre RB, Eyzaguirre LM, Carr JK, Blattner WA, Roye ME.

AIDS Res Hum Retroviruses. 2015 Sep;31(9):932-7. doi: 10.1089/AID.2015.0122. Epub 2015 Aug 5.

PMID:
26122980
18.

HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population.

Riedel DJ, Rositch AF, Redfield RR, Blattner WA.

Leuk Lymphoma. 2016 Feb;57(2):306-312. doi: 10.3109/10428194.2015.1055483. Epub 2015 Jun 19.

PMID:
26025299
19.

Socio-Demographic and Adherence Factors Associated with Viral Load Suppression in HIV-Infected Adults Initiating Therapy in Northern Nigeria: A Randomized Controlled Trial of a Peer Support Intervention.

Coker M, Etiebet MA, Chang H, Awwal G, Jumare J, Musa BM, Babashani M, Habib AG, Dakum P, Abimiku AG, Charurat ME, Blattner WA, Eng M, Ndembi N.

Curr HIV Res. 2015;13(4):279-85.

PMID:
25845393
20.

Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid Among Clinical Mycobacteria Isolates in Ilorin, Nigeria.

Nwofor AC, Nyamngee A, Nwabuisi C, Iwakun M, Gidado M, Mensah C, Dakum P, Agbede OO, Ndembi N, Blattner WA, Abimiku AG.

Curr HIV Res. 2015;13(4):308-14.

PMID:
25845392
21.

HIV-1 Antiretroviral Drug Resistance in Pregnant Women in Jamaica: A Preliminary Report.

Amarakoon II, Ramkissoon A, Pierre R, Eyzaguirre LM, Carr JK, Blattner WA, Roye ME.

West Indian Med J. 2014 Jul 3;63(6):596-600. doi: 10.7727/wimj.2014.016. Epub 2014 Aug 21.

22.

Correlates of Patient Retention in HIV Care and Treatment Programs in Nigeria.

Ugoji C, Okere N, Dakum P, Ake-Uzoigwe R, Igboelina D, Ndembi N, Ekong E, Charurat M, Blattner WA.

Curr HIV Res. 2015;13(4):300-7.

PMID:
25777516
23.

Adherence to Anti-Retroviral Therapy in North Central Nigeria.

Avong YK, van Wyk B, Njab J, Abimiku AG, Ndembi N, Okuma J, Ogbanufe O, Ekong E, Dakum P, Blattner WA.

Curr HIV Res. 2015;13(4):268-78.

PMID:
25642849
24.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

25.

Screening test for HTLV-III (AIDS agent) antibodies: specificity, sensitivity, and applications.

Weiss SH, Goedert JJ, Sarngadharan MG, Bodner AJ; AIDS Seroepidemiology Collaborative Working Group, Gallo RC, Blattner WA.

JAMA. 2014 Jul 23-30;312(4):442. doi: 10.1001/jama.2013.279636. No abstract available.

PMID:
25038372
26.

Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria.

Akolo C, Royal W 3rd, Cherner M, Okwuasaba K, Eyzaguirre L, Adebiyi R, Umlauf A, Hendrix T, Johnson J, Abimiku A, Blattner WA.

J Neurovirol. 2014 Aug;20(4):380-7. doi: 10.1007/s13365-014-0254-6. Epub 2014 Jun 14.

27.

Elevated hypermutation levels in HIV-1 natural viral suppressors.

Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM.

Virology. 2013 Sep 1;443(2):306-12. doi: 10.1016/j.virol.2013.05.019. Epub 2013 Jun 19.

28.

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.

Yates NL, Stacey AR, Nolen TL, Vandergrift NA, Moody MA, Montefiori DC, Weinhold KJ, Blattner WA, Borrow P, Shattock R, Cohen MS, Haynes BF, Tomaras GD.

Mucosal Immunol. 2013 Jul;6(4):692-703. doi: 10.1038/mi.2012.107. Epub 2013 Jan 9.

29.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, Elegba O, Ndembi N, Abimiku A, Carr JK, Eyzaguirre LM, Blattner WA.

AIDS. 2013 Feb 20;27(4):553-61. doi: 10.1097/QAD.0b013e32835b0f59.

30.

Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria.

Royal W 3rd, Cherner M, Carr J, Habib AG, Akomolafe A, Abimiku A, Charurat M, Farley J, Oluyemisi A, Mamadu I, Johnson J, Ellis R, McCutchan JA, Grant I, Blattner WA.

J Neurovirol. 2012 Jun;18(3):191-9. doi: 10.1007/s13365-012-0097-y. Epub 2012 Apr 18. Erratum in: J Neurovirol. 2012 Oct;18(5):441. McCutchen, J Allen [corrected to McCutchan, J Allen].

31.

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR; NIAID HIV Vaccine Trials Network.

PLoS One. 2012;7(1):e29231. doi: 10.1371/journal.pone.0029231. Epub 2012 Jan 5.

32.

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.

Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B.

PLoS Pathog. 2011 Sep;7(9):e1002209. doi: 10.1371/journal.ppat.1002209. Epub 2011 Sep 29.

33.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R; NIAID HIV Vaccine Trials Network 044 Study Team.

J Infect Dis. 2011 Nov 15;204(10):1541-9. doi: 10.1093/infdis/jir615. Epub 2011 Sep 21.

34.

Significantly longer envelope V2 loops are characteristic of heterosexually transmitted subtype B HIV-1 in Trinidad.

Collins-Fairclough AM, Charurat M, Nadai Y, Pando M, Avila MM, Blattner WA, Carr JK.

PLoS One. 2011;6(6):e19995. doi: 10.1371/journal.pone.0019995. Epub 2011 Jun 17.

35.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

36.

HIV-1 epidemic in the Caribbean is dominated by subtype B.

Nadai Y, Eyzaguirre LM, Sill A, Cleghorn F, Nolte C, Charurat M, Collado-Chastel S, Jack N, Bartholomew C, Pape JW, Figueroa P, Blattner WA, Carr JK.

PLoS One. 2009;4(3):e4814. doi: 10.1371/journal.pone.0004814. Epub 2009 Mar 12.

37.

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.

38.

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF.

J Virol. 2008 Dec;82(24):12449-63. doi: 10.1128/JVI.01708-08. Epub 2008 Oct 8.

39.

Adherence to anti retroviral therapy (ART) during Muslim Ramadan fasting.

Habib AG, Shepherd JC, Eng MK, Babashani M, Jumare J, Yakubu U, Gebi UI, Saad M, Ibrahim H, Blattner WA.

AIDS Behav. 2009 Feb;13(1):42-5. doi: 10.1007/s10461-008-9412-2. Epub 2008 Jun 3.

40.

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.

41.

Protocol for nearly full-length sequencing of HIV-1 RNA from plasma.

Nadai Y, Eyzaguirre LM, Constantine NT, Sill AM, Cleghorn F, Blattner WA, Carr JK.

PLoS One. 2008 Jan 9;3(1):e1420. doi: 10.1371/journal.pone.0001420.

42.

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12.

43.

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network.

Vaccine. 2007 Jan 5;25(3):510-8. Epub 2006 Aug 10.

PMID:
17049679
44.

High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2005 Oct 1;192(7):1249-59. Epub 2005 Aug 31.

PMID:
16136469
45.

Risk factors for in utero and intrapartum transmission of HIV.

Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, LaRussa P, Landesman S, Rich KC.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):87-95.

PMID:
15608531
46.

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.

Blattner WA, Oursler KA, Cleghorn F, Charurat M, Sill A, Bartholomew C, Jack N, O'Brien T, Edwards J, Tomaras G, Weinhold K, Greenberg M.

J Infect Dis. 2004 May 15;189(10):1793-801. Epub 2004 Apr 26.

PMID:
15122515
47.

A cohort study of health effects of human T-cell lymphotropic virus type I infection in Jamaican children.

Maloney EM, Wiktor SZ, Palmer P, Cranston B, Pate EJ, Cohn S, Kim N, Miley W, Thomas TL, Blattner WA, Hanchard B.

Pediatrics. 2003 Aug;112(2):e136-42.

PMID:
12897319
48.

Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.

Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA; Women and Infants Transmission Study (WITS) Group.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):175-83.

PMID:
12794551
49.

Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA.

Goedert JJ, Charurat M, Blattner WA, Hershow RC, Pitt J, Diaz C, Mofenson LM, Green K, Minkoff H, Paul ME, Thomas DL, Whitby D; Women and Infants Transmission Study.

AIDS. 2003 Feb 14;17(3):425-33.

PMID:
12556697
50.

Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy.

Constantine NT, Sill AM, Jack N, Kreisel K, Edwards J, Cafarella T, Smith H, Bartholomew C, Cleghorn FR, Blattner WA.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):94-103.

PMID:
12514420

Supplemental Content

Loading ...
Support Center